ERBB2 and breast cancer: Preclinically, ORM-5029 demonstrated 10–1000 fold increased potency in HER2-expressing cell lines versus SMol006, T-DM1, and/or T-DXd monotherapies as well as antitumor efficacy in BC cell line xenografts superior to T-DM1 and comparable to T-DXd [202].